209 related articles for article (PubMed ID: 11384101)
1. p53 mutations in urinary bladder cancer.
Berggren P; Steineck G; Adolfsson J; Hansson J; Jansson O; Larsson P; Sandstedt B; Wijkström H; Hemminki K
Br J Cancer; 2001 Jun; 84(11):1505-11. PubMed ID: 11384101
[TBL] [Abstract][Full Text] [Related]
2. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
[TBL] [Abstract][Full Text] [Related]
3. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer.
Phillips HA; Howard GC; Miller WR
Br J Cancer; 2000 Jan; 82(1):136-41. PubMed ID: 10638980
[TBL] [Abstract][Full Text] [Related]
5. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H
J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045
[TBL] [Abstract][Full Text] [Related]
6. Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms.
Yamaguchi K; Sugano K; Fukayama N; Nakashima Y; Saotome K; Yokoyama T; Yokota T; Ohkura H
Am J Gastroenterol; 1997 Feb; 92(2):307-12. PubMed ID: 9040212
[TBL] [Abstract][Full Text] [Related]
7. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
8. DNA polymerase beta gene mutations in human bladder cancer.
Matsuzaki J; Dobashi Y; Miyamoto H; Ikeda I; Fujinami K; Shuin T; Kubota Y
Mol Carcinog; 1996 Jan; 15(1):38-43. PubMed ID: 8561864
[TBL] [Abstract][Full Text] [Related]
9. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences.
Dahse R; Gärtner D; Werner W; Schubert J; Junker K
Oncol Rep; 2003; 10(6):2033-7. PubMed ID: 14534739
[TBL] [Abstract][Full Text] [Related]
10. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
11. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
12. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
[TBL] [Abstract][Full Text] [Related]
13. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
15. Influence of cigarette smoking on P53 gene mutations in bladder carcinomas.
Bernardini S; Adessi GL; Chezy E; Billerey C; Carbillet JP; Bittard H
Anticancer Res; 2001; 21(4B):3001-4. PubMed ID: 11712801
[TBL] [Abstract][Full Text] [Related]
16. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients.
Domínguez G; Carballido J; Silva J; Silva JM; García JM; Menéndez J; Provencio M; España P; Bonilla F
Clin Cancer Res; 2002 Apr; 8(4):980-5. PubMed ID: 11948103
[TBL] [Abstract][Full Text] [Related]
17. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.
Spruck CH; Rideout WM; Olumi AF; Ohneseit PF; Yang AS; Tsai YC; Nichols PW; Horn T; Hermann GG; Steven K
Cancer Res; 1993 Mar; 53(5):1162-6. PubMed ID: 8439962
[TBL] [Abstract][Full Text] [Related]
18. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
19. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
20. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
